methyl 3-(2-aminothiazol-4-yl)benzoate | 862389-45-5

• 物质功能分类: 化学试剂 - 有机试剂 - 酯类
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: methyl 3-(2-aminothiazol-4-yl)benzoate
• 英文别名: methyl 3-(2-amino-1,3-thiazol-4-yl)benzoate
• CAS: 862389-45-5
• 化学式: C₁₁H₁₀N₂O₂S
• 分子量: 234.279
• InChiKey: DKNFFLRDWGIADF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  93.4
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  methyl 3-(2-aminothiazol-4-yl)benzoate 在 N-甲基吗啉 、 吡啶 、 N,O-双三甲硅基乙酰胺 、 苯甲醚 、 三氟乙酸 、 sodium hydroxide 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 反应 1.0h， 生成 (7R)-3-(acetyloxymethyl)-7-[[3-(2-amino-1,3-thiazol-4-yl)benzoyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
  参考文献：
  名称：

  Design and synthesis of 2-aminothiazole based antimicrobials targeting MRSA

  摘要：

  Privileged structure-based libraries have been shown to provide high affinity lead compounds for a variety of important biological targets. The present study describes the synthesis and screening of a 2-aminothiazole based compound library to determine their utility as antimicrobials, focusing on MRSA. Several of the compounds in this series demonstrated improved antimicrobial activity as compared to ceftriaxone (CTX), a beta-lactam antibiotic. The most potent compound (21) had MICs in the range of 24 mu g/ml across a panel of Staphylococcus aureus strains. In addition, trifluoromethoxy substituted aminothiazoles and aminobenzothiazoles were found to be potent antimicrobials with MICs of 2-16 mu g/ml. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.09.095
• 作为产物：
  描述：

  3-乙酰基苯甲酸 在 碘 作用下， 以 甲醇 、 正己烷 、 甲苯 为溶剂， 反应 0.33h， 生成 methyl 3-(2-aminothiazol-4-yl)benzoate
  参考文献：
  名称：

  Design and synthesis of 2-aminothiazole based antimicrobials targeting MRSA

  摘要：

  Privileged structure-based libraries have been shown to provide high affinity lead compounds for a variety of important biological targets. The present study describes the synthesis and screening of a 2-aminothiazole based compound library to determine their utility as antimicrobials, focusing on MRSA. Several of the compounds in this series demonstrated improved antimicrobial activity as compared to ceftriaxone (CTX), a beta-lactam antibiotic. The most potent compound (21) had MICs in the range of 24 mu g/ml across a panel of Staphylococcus aureus strains. In addition, trifluoromethoxy substituted aminothiazoles and aminobenzothiazoles were found to be potent antimicrobials with MICs of 2-16 mu g/ml. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.09.095

文献信息

• Tricyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-kB activity and use thereof
  申请人：Weinstein S. David

  公开号：US20050187242A1

  公开（公告）日：2005-08-25

  Novel non-steroidal compounds are provided which are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-κB activity including obesity, diabetes, inflammatory and immune diseases, and have the structure of formula (I) or stereoisomers or prodrugs or pharmaceutically acceptable salts thereof, wherein B, J, K, Z, R, R a , R b , R c , R d , R q , R w , m and n are defined herein. Also provided are pharmaceutical compositions and methods of treating obesity, diabetes and inflammatory or immune associated diseases comprising said compounds.

  提供了一种新型的非甾体化合物，可用于治疗与糖皮质激素受体、AP-1和/或NF-κB活性调节相关的疾病，包括肥胖、糖尿病、炎症和免疫性疾病，并具有以下结构的化学式（I）或其立体异构体或前药或其药用可接受盐，其中B、J、K、Z、R、Ra、Rb、Rc、Rd、Rq、Rw、m和n在此处被定义。还提供了包含所述化合物的药物组合物和治疗肥胖、糖尿病以及炎症或免疫相关疾病的方法。
• [EN] HETEROCYCLYLAMIDES AS GUT MICROSOMAL TRIGLYCERIDE TRANSPORT PROTEIN INHIBITORS<br/>[FR] HÉTÉROCYCLYLAMIDES COMME INHIBITEURS DE LA PROTÉINE DE TRANSPORT DE TRIGLYCÉRIDES MICROSOMAL DE L'INTESTIN
  申请人：SIRTRIS PHARMACEUTICALS INC

  公开号：WO2009014674A1

  公开（公告）日：2009-01-29

  Compounds represented by formula (I) are inhibitors of gut microsomal triglyceride transfer protein. Such compounds are useful in treating diseases or conditions such as diabetes and obesity, along with patients are risk for developing such diseases or conditions.

  公式（I）代表的化合物是肠道微粒三酰甘油转移蛋白的抑制剂。这些化合物在治疗糖尿病和肥胖等疾病或病症方面非常有用，同时还适用于患有这些疾病或病症风险的患者。
• Gut microsomal triglyceride transport protein inhibitors
  申请人：Vu Chi B.

  公开号：US20080249130A1

  公开（公告）日：2008-10-09

  Compounds represented by formula (I): are inhibitors of gut microsomal triglyceride transfer protein. Such compounds are useful in treating diseases or conditions such as diabetes and obesity, along with patients are risk for developing such diseases or conditions.

  化学式（I）所代表的化合物是肠道微粒体甘油三酯转移蛋白的抑制剂。这些化合物在治疗糖尿病和肥胖等疾病或病况的患者以及患有这些疾病或病况的风险患者中非常有用。
• WO2008/100423
  申请人：——

  公开号：——

  公开（公告）日：——
• TRICYCLIC MODULATORS OF THE GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF
  申请人：Weinstein S. David

  公开号：US20070270453A1

  公开（公告）日：2007-11-22

  Novel non-steroidal compounds are provided which are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-κB activity including obesity, diabetes, inflammatory and immune diseases, and have the structure of formula (I) or stereoisomers or prodrugs or pharmaceutically acceptable salts thereof, wherein B, J, K, Z, R, R a , R b , R c , R d , R q , R w , m and n are defined herein. Also provided are pharmaceutical compositions and methods of treating obesity, diabetes and inflammatory or immune associated diseases comprising said compounds.